Zobrazeno 1 - 10
of 130
pro vyhledávání: ''
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Shaima’a Hamarsheh, Justus Duyster, Lukas Braun, Franziska M. Uhl, Sandra Duquesne, Geoffroy Andrieux, Robert Zeiser, Melanie Boerries, Annette Schmitt-Graeff, Lena Osswald, Christine Dierks, Tilman Brummer, Claudius Klein
Publikováno v:
Molecular Cancer Research. 19:1596-1608
The bone marrow microenvironment (BMME) is key player in regulation and maintenance of hematopoiesis. Oncogenic RAS mutations, causing constitutive activation of multiple tumor-promoting pathways, are frequently found in human cancer. So far in hemat
Autor:
Carsten Sticht, Carolin Mogler, Olga Ermakova, Fabian Rose, Stefan Thomann, Eduard Ryschich, Carolina De La Torre, Daniel Kazdal, Kai Breuhahn, Claudia R. Ball, Norbert Gretz, Stephanie Roessler, Simone Marquard, Sarah Fritzsche, Peter Schirmacher, S Weiler, Teng Wei, Eugen Rempel, Hanno Glimm, Marcell Tóth
Publikováno v:
Cancer Research. 80:5502-5514
The oncogene yes-associated protein (YAP) controls liver tumor initiation and progression via cell extrinsic functions by creating a tumor-supporting environment in conjunction with cell autonomous mechanisms. However, how YAP controls organization o
Autor:
Michael J. Schell, Michael Nebozhyn, W. Jack Pledger, Jiannong Li, Jamie K. Teer, Mingli Yang, Timothy J. Yeatman, Andrey Loboda
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 28:1141-1152
Background: EGFR is a major therapeutic target for colorectal cancer. Currently, extended RAS/RAF testing identifies only nonresponders to EGFR inhibitors (EGFRi). We aimed to develop a mutation signature that further refines drug-sensitive subpopula
Autor:
Raghu Kalluri, Valerie S. LeBleu, Yingqi Teng, Hans Petter Eikesdal, Julienne L. Carstens, Hikaru Sugimoto, Lisa M. Becker, Keizo Kanasaki, Akane Kizu
Publikováno v:
Molecular Cancer Research. 16:1568-1578
Deregulated transforming growth factor-β (TGFβ) signaling is a common feature of many epithelial cancers. Deletion of TGFβ receptor type 2 (TGFBR2) in fibroblast specific protein-1 (FSP1)-positive stromal cells induces squamous cell carcinoma in t
Autor:
Tobias Herold, Luise Hartmann, Wolfgang Hiddemann, Philipp A. Greif, Daniela Schumacher, Bianka Ksienzyk, Claudia D. Baldus, Bernhard Wörmann, Evelyn Zellmeier, Stephan Wolf, Sebastian Vosberg, Friederike Pastore, Helmut Blum, Stephanie Schneider, Sophie M. Stief, Stefanos A. Bamopoulos, Wolfgang E. Berdel, Ines Hellmann, Stefan Krebs, Alexander Graf, Karsten Spiekermann, Klaus H. Metzeler, Stefan K. Bohlander, Vindi Jurinovic, Nikola P. Konstandin, Raphael Mattes, Dennis Görlich, Martin Neumann, Kathrin Bräundl, Paul Kerbs
Publikováno v:
Clinical Cancer Research. 24:1716-1726
Purpose: To study mechanisms of therapy resistance and disease progression, we analyzed the evolution of cytogenetically normal acute myeloid leukemia (CN-AML) based on somatic alterations. Experimental Design: We performed exome sequencing of matche
Publikováno v:
Cancer Research. 81:1323-1323
In this study, we develop a novel autophagy inhibitor targeting one of the most aggressive cell populations present in pancreatic tumors, the pancreatic cancer stem cell (CSC). Targeting this population which has the malignant properties of tumorigen
Autor:
Christian A. Hassig, Nam-Phuong Nguyen, Dean Perusse, Kristen M. Turner, Jason Christiansen, Laurence Jadin
Publikováno v:
Cancer Research. 81:1089-1089
Introduction: Tumors with oncogene copy number amplification are aggressive, have poor prognosis and, to date, have been very difficult to treat. Computational analyses in a large pan-cancer study revealed that ecDNA comprises over 50% of highly ampl
Publikováno v:
Cancer Research. 81:419-419
Background Although studies have identified several clinicopathological factors that can predict the response to and survival on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), few studies have clearly demonstrated the effect
Publikováno v:
Cancer Research. 81:2596-2596
Chemopreventive efficacy of p-XSC is well documented but it failed due to systemic toxicity issues. This toxicity could partially be due to the release of poisonous hydrogen cyanide generated after p-XSC metabolizes to form active bis-selenol (p-XSeH